Las mutaciones somáticas activadoras PTPN11 están presentes en ~35% de los casos de LMMJ y definen los...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-PTPN11-JMML |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-05-04 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-JMML |
| Fuentes | SRC-COG |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-PTPN11 |
|---|---|
| Variante | mutación somática activadora PTPN11 (E76K, D61G, Q79R) — JMML; CRÍTICO: distinguir somática (JMML, requiere HCT) vs germline/síndrome de Noonan (puede auto-resolverse) |
| Enfermedad | DIS-JMML |
| El nivel de ESCAT | IIIA |
| Combinaciones recomendadas | azacitidine 75 mg/m² SC days 1–5 q28d — bridge to alloHCT in JMML; multiple cycles if needed for response/MRD reduction, allogeneic HCT (MRD10/MUD/haplo) — curative intent; somatic PTPN11 indicates high urgency for HCT, SHP2 inhibitor (RMC-4630, TNO155, ERAS-601) — investigational; pediatric expansion cohorts; clinical trial preferred |
| Resumen de las pruebas | PTPN11 somatic activating mutations are present in ~35% of JMML cases and define the most common molecular driver of this disease. The mutation drives constitutive SHP2/ RAS/MAPK signaling. Allogeneic HCT is the only established curative treatment for JMML (5-year EFS ~50–55%). Molecular markers guide HCT urgency: somatic PTPN11 is associated with worse prognosis and shorter time to progression vs CBL or NRAS mutations. Azacitidine (5-day schedule) is used as bridge to HCT, with some evidence of responses (phase II: ORR ~20–30%) and MRD reduction pre-transplant. Investigational SHP2 inhibitors (RMC-4630, TNO155, ERAS-601) have JMML/pediatric expansion cohorts in phase I. MEK inhibitors (trametinib) also under evaluation in PTPN11-mutant JMML given downstream pathway convergence. ESCAT IIIA: somatic PTPN11 is prognostically relevant and the molecular target of SHP2 inhibitors in development; HCT remains standard; no approved SHP2 inhibitor. Germline PTPN11 (Noonan syndrome): different clinical entity — watch-and-wait approach often appropriate; HCT not usually needed for Noonan myelo... |
Notas
ESCAT IIIA: somatic PTPN11 in JMML is a validated prognostic biomarker and molecular target of investigational SHP2 inhibitors. HCT is the only proven curative option. CRITICAL CLINICAL DISTINCTION: Noonan syndrome-associated myeloproliferation (germline PTPN11) is typically self-limiting and does NOT require HCT — over-treatment with HCT in Noonan patients carries significant morbidity without benefit. Always confirm somatic vs germline origin of PTPN11 mutation before committing to HCT. Methods: compare tumor (bone marrow) vs germline (buccal swab/saliva) allele frequency; variant frequency >25–30% in bone marrow with homozygous loss suggests somatic with uniparental disomy. Post-HCT relapse: high (25–30%); salvage with second HCT or investigational agent. MRD monitoring by quantitative PCR for PTPN11 mutation pre/post HCT has predictive value for relapse risk.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.